Ethris GmbH

The promise of mRNA therapeutics has been held back by a fundamental physical limitation: lipid nanoparticles containing mRNA are inherently fragile and prone to aggregation when subjected to the mech

The biopharmaceutical industry finds itself at a critical juncture in early 2025, confronting unprecedented levels of geopolitical uncertainty and market disruption. The sector faces fundamental chall

The Bill and Melinda Gates Foundation spent $100bn on public health and anti-poverty initiatives globally during its first 25 years, including investments in private biotechnology companies working in

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Oak Hill Licenses Roche’s Rugonersen,